Michael J. Fox Foundation Tops $2.5 Billion for Parkinson's Research as New Therapies Advance
Updated
Updated · KSL.com · Jun 9
Michael J. Fox Foundation Tops $2.5 Billion for Parkinson's Research as New Therapies Advance
3 articles · Updated · KSL.com · Jun 9
Summary
$2.5 billion in Michael J. Fox Foundation funding has helped accelerate Parkinson's research as care improves symptom control and quality of life, even though no cure exists.
Levodopa remains the mainstay treatment, while Deep Brain Stimulation and focused ultrasound are expanding options by targeting brain regions tied to motor symptoms.
Emerging work is pushing beyond symptom relief into disease-modifying drugs, gene therapy and biomarker discovery aimed at earlier diagnosis and more targeted treatment.
Up to 20% of Parkinson's patients do not have tremors, and non-motor symptoms such as sleep disorders, anxiety, constipation and cognitive changes can appear years earlier.
Young-onset cases affect people under 50, underscoring the need for early diagnosis, proactive management and support services for patients and caregivers.
Parkinson's has many invisible signs. Can new biomarkers help detect the disease years earlier than tremors appear?
Young-Onset Parkinson's has unique genetic roots. Could this discovery lead to targeted therapies for patients diagnosed before age 50?
With gene therapy now in clinical trials, how close are we to slowing Parkinson's progression, not just treating its symptoms?
Accelerating the Cure: How the Michael J. Fox Foundation’s $270 Million Investment is Transforming Parkinson’s Disease Research and Patient Care
Overview
The Michael J. Fox Foundation (MJFF) is driving major progress in Parkinson’s disease research by funding innovative therapies and diagnostic tools. With the ambitious goal of eliminating Parkinson’s within 30 to 40 years, MJFF supports both scientific breakthroughs and community advocacy, such as Proposition 14. A recent example is the $1 million grant to Montara Therapeutics to develop treatments that enhance autophagy, a process that helps clear toxic proteins and may slow disease progression. Through targeted investments and a focus on collaboration, MJFF brings hope and tangible advancements to families affected by Parkinson’s.